Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PE
PepGen Inc. Common Stock
PEPG
Mkt Cap
$178.9M
Volume
1.12M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PE
PEPG
PE
PepGen Inc. Common Stock
PEPG
News
·
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
Mkt Cap
$175.2M
Volume
1.12M
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
GlobeNewswire Inc. · Apr 21, 2026
S&P 500 Falls 1%; Accenture Posts Upbeat Earnings
U.S. stocks traded lower midday, with the S&P 500 dropping 1%. Accenture reported strong Q4 earnings, beating analyst estimates, while several other companies experienced significant stock price movements.
Benzinga · Sep 25, 2025
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
Benzinga · Sep 25, 2025
PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against PepGen alleging false and misleading statements about the company's drug PGN-EDO51, its CONNECT2 study effectiveness, and clinical prospects during the period of March 7, 2024 to March 3, 2025.
GlobeNewswire Inc. · Aug 7, 2025
PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Law firm announces class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its drug PGN-EDO51 and clinical study CONNECT2 between March 2024 and March 2025.
GlobeNewswire Inc. · Aug 7, 2025
PepGen (PEPG) Q2 Loss Narrows 19.5%
Biotechnology company PepGen reported Q2 2025 earnings with a narrower net loss of $(0.70) per share, better than analyst expectations. The company continues developing oligonucleotide therapies for neuromuscular diseases and expects to share clinical trial data in Q4 2025 and Q1 2026.
The Motley Fool · Aug 7, 2025
PEPGEN (PEPG) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against PepGen alleging false and misleading statements about their drug PGN-EDO51's effectiveness and safety during the period of March 7, 2024 to March 3, 2025.
GlobeNewswire Inc. · Aug 5, 2025
Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG
Pomerantz LLP filed a class action lawsuit against PepGen Inc. for allegedly making false and misleading statements about its Duchenne muscular dystrophy drug PGN-EDO51, which failed to meet clinical trial expectations and was ultimately discontinued.
GlobeNewswire Inc. · Aug 5, 2025
PEPG FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important August 8 Deadline in Securities Class Action – PEPG
Rosen Law Firm is alerting PepGen Inc. investors about an August 8, 2025 deadline for a securities class action lawsuit, alleging the company made false and misleading statements about its drug PGN-EDO51 and clinical study effectiveness.
GlobeNewswire Inc. · Aug 3, 2025
מועד אחרון לתביעה נגד PEPG: רוזן, יועץ למשקיעים מוביל, מעודד את משקיעי PepGen Inc להשיג ייעוץ לפני המועד האחרון החשוב של 8 באוגוסט בתביעה ייצוגית בניירות ערך - PEPG
Rosen Law Firm reminds PepGen Inc. investors of an August 8, 2025 deadline to join a securities class action lawsuit, alleging the company made false statements about its drug PGN-EDO51's clinical research and effectiveness.
GlobeNewswire Inc. · Aug 3, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PE
PEPG
PepGen Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PEPG
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PEPG yet.
Related Tickers
Earnings